Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9974929 | The Journal of Heart and Lung Transplantation | 2005 | 6 Pages |
Abstract
In the setting of tertiary referral centers, ROS appears to be safe and effective in lowering LDL-C in OHT recipients in whom treatment with other statins failed to achieve target LDL-C. No evidence of liver or muscle dysfunction was noted. Long-term studies are needed to ascertain the effect of ROS therapy on incidence of coronary artery disease (CAD) in this population.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
A. MD, C. RN, L. MD, J. MD, K. DSc, A. MD,